683 related articles for article (PubMed ID: 9751354)
1. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
3. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
[TBL] [Abstract][Full Text] [Related]
4. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
[TBL] [Abstract][Full Text] [Related]
5. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
6. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
7. Finasteride for benign prostatic hyperplasia.
Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
[TBL] [Abstract][Full Text] [Related]
8. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Wilt TJ; Howe W; MacDonald R
BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
[TBL] [Abstract][Full Text] [Related]
9. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks I; Macdonald R
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
[TBL] [Abstract][Full Text] [Related]
10. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Mudiyala R; Ahmed A
J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
Hillman AL; Schwartz JS; Willian MK; Peskin E; Roehrborn CG; Oesterling JE; Mason MF; Maurath CJ; Deverka PA; Padley RJ
Urology; 1996 Feb; 47(2):169-78. PubMed ID: 8607228
[TBL] [Abstract][Full Text] [Related]
14. 5alpha-reductase inhibitors: what role should they play?
Kaplan SA
Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
[TBL] [Abstract][Full Text] [Related]
16. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
Roehrborn CG; Oesterling JE; Olson PJ; Padley RJ
Urology; 1997 Oct; 50(4):556-61. PubMed ID: 9338731
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
18. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
[TBL] [Abstract][Full Text] [Related]
19. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
20. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.
Boyle P; Gould AL; Roehrborn CG
Urology; 1996 Sep; 48(3):398-405. PubMed ID: 8804493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
